Literature DB >> 19381125

Treatment regimens for non-alcoholic fatty liver disease.

Brian P Lam1, Zobair M Younossi.   

Abstract

With the growing epidemic of obesity and diabetes, more attention has been placed on metabolic syndrome and its associated hepatic manifestation, non-alcoholic fatty liver disease (NAFLD). Within the spectrum of clinico-pathologic conditions known as NAFLD, only a minority of patients has the histological features characteristic of non-alcoholic steatohepatitis (NASH), which has the potential to progress to cirrhosis and hepatocellular carcinoma. Therefore, diagnosis and therapy should target patients with NASH. Current treatment recommendations include weight loss and the reversal of other components of metabolic syndrome, but several other treatment modalities are under investigation. To date, no pharmacologic treatment has been reliably shown to be effective for NASH. This article reviews all available treatment modalities, including lifestyle changes, bariatric surgery, weight loss medications, insulin sensitizers, lipid lowering agents, antioxidants, cytoprotective agents, and other novel treatments.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19381125

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  14 in total

1.  Mitochondrial dysfunction in obesity-associated nonalcoholic fatty liver disease: the protective effects of pomegranate with its active component punicalagin.

Authors:  Xuan Zou; Chunhong Yan; Yujie Shi; Ke Cao; Jie Xu; Xun Wang; Cong Chen; Cheng Luo; Yuan Li; Jing Gao; Wentao Pang; Jialong Zhao; Fei Zhao; Hao Li; Adi Zheng; Wenyan Sun; Jiangang Long; Ignatius Man-Yau Szeto; Youyou Zhao; Zhizhong Dong; Peifang Zhang; Junkuan Wang; Wuyuan Lu; Yong Zhang; Jiankang Liu; Zhihui Feng
Journal:  Antioxid Redox Signal       Date:  2014-02-18       Impact factor: 8.401

2.  Combination drug treatment in patients with non-alcoholic fatty liver disease.

Authors:  Theodosios D Filippatos; Moses S Elisaf
Journal:  World J Hepatol       Date:  2010-04-27

Review 3.  Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease.

Authors:  Michael S Kostapanos; Anastazia Kei; Moses S Elisaf
Journal:  World J Hepatol       Date:  2013-09-27

4.  Hepatoprotective effects of Spirulina maxima in patients with non-alcoholic fatty liver disease: a case series.

Authors:  Aldo Ferreira-Hermosillo; Patricia V Torres-Duran; Marco A Juarez-Oropeza
Journal:  J Med Case Rep       Date:  2010-04-07

5.  Resveratrol and fenofibrate ameliorate fructose-induced nonalcoholic steatohepatitis by modulation of genes expression.

Authors:  Enas A Abd El-Haleim; Ashraf K Bahgat; Samira Saleh
Journal:  World J Gastroenterol       Date:  2016-03-14       Impact factor: 5.742

6.  A Randomized Controlled Trial Comparing Efficacy of Pentoxifylline and Pioglitazone on Metabolic Factors and Liver Histology in Patients with Non-alcoholic Steatohepatitis.

Authors:  Barjesh C Sharma; Ajay Kumar; Vishal Garg; Ravi S Reddy; Puja Sakhuja; Shiv K Sarin
Journal:  J Clin Exp Hepatol       Date:  2012-11-06

7.  Docosahexaenoic acid attenuates hepatic inflammation, oxidative stress, and fibrosis without decreasing hepatosteatosis in a Ldlr(-/-) mouse model of western diet-induced nonalcoholic steatohepatitis.

Authors:  Christopher M Depner; Kenneth A Philbrick; Donald B Jump
Journal:  J Nutr       Date:  2013-01-09       Impact factor: 4.798

8.  NCX 1000 Alone or in Combination with Vitamin E Reverses Experimental Nonalcoholic Steatohepatitis in the Rat Similarly to UDCA.

Authors:  Yara Haddad; Diane Vallerand; Antoine Brault; Jean Spénard; Pierre S Haddad
Journal:  Int J Hepatol       Date:  2011-10-16

9.  Hepatoprotective effect of commercial herbal extracts on carbon tetrachloride-induced liver damage in Wistar rats.

Authors:  Paula Cordero-Pérez; Liliana Torres-González; Marcelino Aguirre-Garza; Carlos Camara-Lemarroy; Francisco Guzmán-de la Garza; Gabriela Alarcón-Galván; Homero Zapata-Chavira; Ma de Jesús Sotelo-Gallegos; Cipactli Nadjedja Torres-Esquivel; Ethel Sánchez-Fresno; Daniel Cantú-Sepúlveda; Gerardo González-Saldivar; Judith Bernal-Ramirez; Linda E Muñoz-Espinosa
Journal:  Pharmacognosy Res       Date:  2013-07

10.  Simvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohepatitis-related liver fibrosis.

Authors:  Wei Wang; Caiyan Zhao; Junying Zhou; Zhen Zhen; Yadong Wang; Chuan Shen
Journal:  PLoS One       Date:  2013-10-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.